SCYX - サイネクシス （SCYNEXIS Inc.） サイネクシスSCYXのチャート
SCYXの企業情報
| symbol | SCYx |
|---|---|
| 会社名 | SCYNEXIS Inc. （サイネクシス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 サイネクシス（SCYNEXIS Inc）は治療ニーズに対応するために抗感染薬を発見・開発・商業化する製薬会社である。同社は、人間にとって深刻かつ生命を脅かす侵襲性真菌感染症を治療するための経口投与および静脈内（IV）薬品SCY-078をリード製品候補として開発する。SCY-078は、感染性真菌にある確定したターゲットをブロックするために設計される新たな化学薬品クラスを代表する。同社はSCY-078のIVおよび経口製剤を開発する。SCY-078は、カンジダとアスペルギルス種の必須成分である真菌細胞壁ポリマーグルカンの合成の強力阻害剤である。同化合物は、エキノカンジンクラスのように、化学修飾によって、グルカン合成の阻害を通じてカンジダとアスペルギルスに対して抗真菌活性を示す天然産物から導出された。 サイネクシスは、米国の創薬開発会社。治療ニ―ズに対応する抗感染薬の発見、開発、商業化に従事。ヒトの生死に関わる侵襲性真菌感染症の治療用経口薬および点滴薬として、SCY-078の開発を手掛ける。また、ウイルス性疾患の治療用向けシクロフィリン阻害剤の使用についての臨床・前臨床プログラムによる研究、開発を行う。 SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Its lead candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class. It is currently under review by the FDA as a treatment for vaginal yeast infections and in late-stage development for multiple life-threatening fungal infections in hospitalized patients. |
| 本社所在地 | 101 Hudson Street Suite 3610 Jersey City NJ 07302-6548 USA |
| 代表者氏名 | Pamela J. Kirby パメラ・J・カービー |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 201-884-5485 |
| 設立年月日 | 36465 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | － |
| url | www.scynexis.com |
| nasdaq_url | https://www.nasdaq.com/symbol/scyx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -28.44600 |
| 終値（lastsale） | 1.22 |
| 時価総額（marketcap） | 57356740.84 |
| 時価総額 | 時価総額（百万ドル） 48.42413 |
| 売上高 | 売上高（百万ドル） 0.25700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 8.09413 |
| 当期純利益 | 当期純利益（百万ドル） -30.75200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 SCYNEXIS Inc revenues increased 1% to $129K. Net loss increased 63% to $14.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Warrant liabilities fair value adjustmen decrease of 85% to $680K (income) Research and development increase of 29% to $10.9M (expense). |
SCYXのテクニカル分析
SCYXのニュース
SCYNEXIS, Inc. (NASDAQ:SCYX) to Post FY2023 Earnings of $1.31 Per Share, Cantor Fitzgerald Forecasts 2023/04/07 06:56:41 The AM Reporter
SCYNEXIS, Inc. (NASDAQ:SCYX – Get Rating) – Equities research analysts at Cantor Fitzgerald boosted their FY2023 earnings per share estimates for SCYNEXIS in a research report issued to clients and investors on Monday, April 3rd. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings of $1.31 per share for the year, […]
Looking Into SCYNEXIS''s Return On Capital Employed 2023/04/03 14:47:27 Benzinga
According to data from Benzinga Pro, during Q4, SCYNEXIS ''s (NASDAQ: SCYX ) reported sales totaled $1.40 million. Despite a 51.23% increase in earnings, the company posted a loss of $14.43 million. In Q3, SCYNEXIS brought in $1.56 million in sales but lost $29.58 million in earnings. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and … Full story available on Benzinga.com
Scynexis: Licensing Deal With GSK, Upgrading To A Hold Rating From A Sell 2023/03/31 15:47:43 Seeking Alpha
SCYNEXIS and GSK signed an exclusive licensing agreement for Brexafemme, an FDA-approved medicine for vulvovaginal candidiasis. Read our updated outlook here.
SCYNEXIS GAAP EPS of -$0.30 beats by $0.10, revenue of $1.4M beats by $0.13M 2023/03/31 12:39:40 Seeking Alpha
SCYNEXIS press release (SCYX): Q4 GAAP EPS of -$0.30 beats by $0.10.Revenue of $1.4M (+133.3% Y/Y) beats by $0.13M.SCYNEXIS ended Q4 2022 with cash, cash equivalents and…
US stock market closes higher, Dow Jones gains 0.43% 2023/03/31 02:25:55 InstaForex
At the same time, there are indicators that hold back the growth of Wall Street, for example, internal macro statistics. So, earlier, the US Department of Commerce lowered the estimate of the country''s GDP growth in the fourth quarter to 2.6% in annual terms (if GDP grew at the same pace for four consecutive quarters), the second estimate was 2.7%, and the first - 2.9% . In the third quarter, US GDP grew by 3.2% on an annualized basis. Data on the labor market also turned out to be worse than expected. US initial jobless claims for the week ending March 25 increased by 7,000 from the previous week to 198,000. The forecast was 196 thousand. At the close in the New York Stock Exchange, the Dow Jones was up 0.43%, the S&P 500 was up 0.57% and the NASDAQ Composite was up 0.73%. The leading performer among the Dow Jones index components today was Intel Corporation (NASDAQ:INTC), which gained 0.57 points or 1.81% to close at 32.09. Boeing Co (NYSE:BA) rose 3.07 points or 1.48% to close at 211.04.
SCYNEXIS''s Return On Capital Employed Overview 2022/12/13 14:48:46 Benzinga
SCYNEXIS (NASDAQ: SCYX ) brought in sales totaling $1.56 million during Q3 according to data provided by Benzinga Pro . However, earnings decreased 121.69%, resulting in a loss of $29.58 million. In Q2, SCYNEXIS brought in $1.32 million in sales but lost $13.35 million in earnings. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a … Full story available on Benzinga.com
SCYX stock on watch after FDA label expansion for anti-fungal therapy (NASDAQ:SCYX) 2022/12/01 14:00:13 Seeking Alpha
SCYNEXIS (SCYX), a biotech focused on treatments for fungal infections, announced Thursday that the FDA approved a second indication for its antifungal therapy Brexafemme.Accordingly,…
Researchers get $3M NIH grant to study Scynexis'' antifungal drug SCY-247 2022/11/30 14:49:47 Seeking Alpha
Scynexis (SCYX) said researchers from Case Western Reserve University in Cleveland were awarded a research grant of more than $3M by the National Institutes of Health ((NIH)) to…
These Numbers Show Just How Powerful SCYNEXIS Inc. (NASDAQ: SCYX) Stock Is 2022/11/28 14:00:00 Stocks Register
SCYNEXIS Inc. (NASDAQ:SCYX) price remained unchanged on Friday, November 25, from its previous close. A look at the daily price movement shows that the last close reads $2.45, with intraday deals fluctuated between $2.43 and $2.47. The company’s 5Y monthly beta was ticking 1.89. Taking into account the 52-week price action we note that the … These Numbers Show Just How Powerful SCYNEXIS Inc. (NASDAQ: SCYX) Stock Is Read More »
SCYNEXIS Inc. (NASDAQ: SCYX) Stock: Boom Or Bust? What Happens Next? 2022/11/19 20:00:00 Marketing Sentinel
During the last session, SCYNEXIS Inc. (NASDAQ:SCYX)’s traded shares were 0.33 million, with the beta value of the company hitting 1.81. At the end of the trading day, the stock’s price was $2.27, reflecting an intraday gain of 10.19% or $0.21. The 52-week high for the SCYX share is $8.10, that puts it down -256.83 … SCYNEXIS Inc. (NASDAQ: SCYX) Stock: Boom Or Bust? What Happens Next? Read More »
SCYX stock on watch after FDA label expansion for anti-fungal therapy (NASDAQ:SCYX) 2022/12/01 14:00:13 Seeking Alpha
SCYNEXIS (SCYX), a biotech focused on treatments for fungal infections, announced Thursday that the FDA approved a second indication for its antifungal therapy Brexafemme.Accordingly,…
Researchers get $3M NIH grant to study Scynexis'' antifungal drug SCY-247 2022/11/30 14:49:47 Seeking Alpha
Scynexis (SCYX) said researchers from Case Western Reserve University in Cleveland were awarded a research grant of more than $3M by the National Institutes of Health ((NIH)) to…
These Numbers Show Just How Powerful SCYNEXIS Inc. (NASDAQ: SCYX) Stock Is 2022/11/28 14:00:00 Stocks Register
SCYNEXIS Inc. (NASDAQ:SCYX) price remained unchanged on Friday, November 25, from its previous close. A look at the daily price movement shows that the last close reads $2.45, with intraday deals fluctuated between $2.43 and $2.47. The company’s 5Y monthly beta was ticking 1.89. Taking into account the 52-week price action we note that the … These Numbers Show Just How Powerful SCYNEXIS Inc. (NASDAQ: SCYX) Stock Is Read More »
SCYNEXIS Inc. (NASDAQ: SCYX) Stock: Boom Or Bust? What Happens Next? 2022/11/19 20:00:00 Marketing Sentinel
During the last session, SCYNEXIS Inc. (NASDAQ:SCYX)’s traded shares were 0.33 million, with the beta value of the company hitting 1.81. At the end of the trading day, the stock’s price was $2.27, reflecting an intraday gain of 10.19% or $0.21. The 52-week high for the SCYX share is $8.10, that puts it down -256.83 … SCYNEXIS Inc. (NASDAQ: SCYX) Stock: Boom Or Bust? What Happens Next? Read More »